Zhang Tingting, Tian Weiwei, Wei Shuang, Lu Xinyi, An Jing, He Shaolong, Zhao Jie, Gao Zhilin, Li Li, Lian Ke, Zhou Qiang, Zhang Huilai, Wang Liang, Su Liping, Kang Huicong, Niu Ting, Zhao Ailin, Pan Jing, Cai Qingqing, Xu Zhenshu, Chen Wenming, Jing Hongmei, Li Peng, Zhao Wanhong, Cao Yang, Mi Jianqing, Chen Tao, Chen Yuan, Zou Ping, Lukacs-Kornek Veronika, Kurts Christian, Li Jian, Liu Xiansheng, Mei Qi, Zhang Yicheng, Wei Jia
Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China.
Department of Hematology, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China.
Exp Hematol Oncol. 2023 Jul 27;12(1):66. doi: 10.1186/s40164-023-00426-x.
The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.
2019冠状病毒病（COVID-19）的爆发给公共卫生系统带来了前所未有的挑战。尽管已采取措施控制疫情，但在一段时间内，COVID-19可能会继续出现散发性爆发，而且个体仍易反复感染。嵌合抗原受体（CAR）-T细胞疗法的接受者具有持久的B细胞发育不全、低丙种球蛋白血症和T细胞多样性丧失的特点，这导致COVID-19感染后重症/危重症病例比例增加和死亡率较高。因此，在考虑CAR-T细胞免疫疗法时，治疗决策变得更加复杂，需要更加谨慎。因此，我们回顾了目前对COVID-19的认识，并报告了COVID-19管理和CAR-T细胞疗法的临床经验。经过小组讨论，我们提出了一个针对CAR-T细胞疗法接受者的合理流程，目的是在COVID-19大流行后的时代最大限度地提高CAR-T细胞疗法的益处。
